RecruitingNot ApplicableNCT07445074

AI-Based Mobile Intervention on Medication Non-Adherence and Transition


Sponsor

University of Central Florida

Enrollment

200 participants

Start Date

May 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA. Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.


Eligibility

Min Age: 14 YearsMax Age: 24 Years

Inclusion Criteria8

  • Diagnosed with epilepsy
  • Currently prescribed anti-seizure medicine (ASMs)
  • Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage)
  • Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study
  • Are between 18-24 years old and able to provide informed consent
  • Able to read, speak, and write in English
  • Resides in Florida
  • Receive outpatient medical services

Exclusion Criteria7

  • They do not own a mobile device with internet access.
  • They have a history of severe intellectual disability.
  • They are unable to operate a mobile device (keyboard or touchscreen).
  • Reside in an in-patient setting.
  • Adults unable to consent.
  • Pregnant women (excluded because pregnancy is not relevant to the study focus).
  • Prisoners.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERMedilepsy® Chatbot AI-Enhanced

Participants in the intervention group will use the AI-personalized version of the Medilepsy® app, which includes a Smart Chatbot that delivers interactive support based on user-entered data. The chatbot offers personalized prompts, relevant topic suggestions, and adaptive educational content to support epilepsy self-management.

OTHERMedilepsy® Chatbot Standard

Participants in the non-intervention group will use a standard version of the Medilepsy® app without AI functionality. This version includes static prompts and general educational links but does not provide personalized feedback or adaptive interaction.


Locations(2)

Orlando Health

Orlando, Florida, United States

University of Central Florida

Orlando, Florida, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07445074


Related Trials